Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Updated . What changed?
Oncorus, Inc. is a biotechnology business based in the US. Oncorus shares (ONCR) are listed on the NASDAQ and all prices are listed in US Dollars. Oncorus employs 51 staff and has a market cap (total outstanding shares value) of USD$347.8 million.
|Latest market close||USD$15.84|
|52-week range||USD$14.6 - USD$19.3|
|50-day moving average||USD$15.9691|
|200-day moving average||USD$15.9691|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-10-23)||2.13%|
|1 month (2020-10-01)||5.60%|
|3 months (2020-07-27)||N/A|
|6 months (2020-04-27)||N/A|
|1 year (2019-10-27)||N/A|
|2 years (2018-10-27)||N/A|
|3 years (2017-10-27)||N/A|
|5 years (2015-10-27)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$347.8 million|
TTM: trailing 12 months
We're not expecting Oncorus to pay a dividend over the next 12 months.
Oncorus, Inc., a clinical stage biopharmaceutical company, focuses to develop viral immunotherapies for cancer patients. Its lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform that it is in Phase I clinical trial to treat various cancers. The company is also developing ONCR-GBM program for treating brain cancer; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Steps to owning and managing MSEX, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVOP, with 24-hour and historical pricing before you buy.
Steps to owning and managing DPS, with 24-hour and historical pricing before you buy.
Steps to owning and managing CLVS, with 24-hour and historical pricing before you buy.
Steps to owning and managing PVH, with 24-hour and historical pricing before you buy.
Steps to owning and managing AXGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ARWR, with 24-hour and historical pricing before you buy.
Steps to owning and managing JCOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing FBM, with 24-hour and historical pricing before you buy.
Steps to owning and managing UHS, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.